Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bio-Rad Laboratories

232.00
+1.540.67%
Post-market: 232.000.00000.00%18:21 EDT
Volume:352.04K
Turnover:81.79M
Market Cap:6.31B
PE:-3.01
High:234.31
Open:230.29
Low:228.64
Close:230.46
Loading ...

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Insider Monkey
·
29 Jan

Press Release: Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Dow Jones
·
28 Jan

Strong week for Bio-Rad Laboratories (NYSE:BIO) shareholders doesn't alleviate pain of three-year loss

Simply Wall St.
·
28 Jan

3 Altcoins That Reached All-Time Low Today — January 27

BE[IN]CRYPTO
·
28 Jan

BIO-UV Group Launches Capital Increase to Fund Growth Initiatives

TIPRANKS
·
24 Jan

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

GlobeNewswire
·
23 Jan

Bell Potter Remains a Buy on Biome Australia Ltd (BIO)

TIPRANKS
·
21 Jan

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Zacks
·
17 Jan

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

Zacks
·
17 Jan

Bio-Rad Laboratories Price Target Maintained With a $481.00/Share by RBC Capital

Dow Jones
·
15 Jan

Bio-Rad Laboratories Led $105 Million Series C Funding Round for Geneoscopy

MT Newswires Live
·
08 Jan

BRIEF-Geneoscopy Closes $105M In Series C Funding Round

Reuters
·
08 Jan

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

THOMSON REUTERS
·
08 Jan

Geneoscopy: Bio-Rad Laboratories Led Financing, Joined by Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, Nt Investments, and Others

THOMSON REUTERS
·
08 Jan

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Business Wire
·
08 Jan

BIO Protocol Announced Long COVID Labs Launch on January 9 to Redefine Medicine Future

CoinMarketCap
·
08 Jan

Getting In Cheap On Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Unlikely

Simply Wall St.
·
07 Jan

BIO-UV Group Reports Semi-Annual Liquidity Contract Balance

TIPRANKS
·
07 Jan

GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025

NewMediaWire
·
06 Jan

Biome Australia Posts Quarterly Sales Revenue Of A$4.6M For Q2

T-Reuters
·
06 Jan